Education
About Us
Working with TipRanks
Follow Us
Kuros Biosciences Ltd. (CH:KURN)
:KURN
KURN Stock Chart & Stats
CHF28.16
-CHF0.35(-1.68%)
At close: 4:00 PM EST
CHF28.16
-CHF0.35(-1.68%)
Day’s Range― - ―
52-Week RangeCHF14.00 - CHF34.20
Previous CloseN/A
Volume98.33K
Average Volume (3M)128.87K
Market Cap
CHF1.01B
Enterprise ValueCHF1.02B
Total Cash (Recent Filing)CHF17.90M
Total Debt (Recent Filing)CHF1.79M
Price to Earnings (P/E)―
Beta1.46
Next Earnings
Mar 10, 2026Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding39,175,300
10 Day Avg. Volume110,510
30 Day Avg. Volume128,868
Financial Highlights & Ratios
PEG Ratio2.90
Price to Book (P/B)13.52
Price to Sales (P/S)10.51
P/FCF Ratio391.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF36.50Price Target Upside29.62% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthA >100% revenue jump demonstrates sustained commercial traction for Kuros's biomaterials across orthopedic and dental channels. This scale expansion supports longer-term market penetration, strengthens distributor leverage, and creates a larger base to absorb fixed costs as the business scales.
High Gross MarginAn 82% gross margin indicates strong product-level economics from proprietary biomaterials. High gross margins provide durable cushion to fund R&D and commercial investment, enabling the company to pursue profitable growth once operating expenses are rationalized.
Improving Cash GenerationPositive operating cash flow and improving free cash flow signal reduced dependence on external financing. This durable improvement enhances financial flexibility to fund commercialization, partnerships, and targeted R&D without immediate capital raises.
Bears Say
Negative Net Profit MarginA negative net margin shows the company still posts losses at the bottom line despite revenue growth. Persistent net losses can erode equity and limit retained capital available for reinvestment unless margins improve sustainably through cost control or higher unit economics.
Negative Operating MarginsNegative EBIT/EBITDA indicate core operations remain loss-making, reflecting elevated SG&A or R&D relative to revenue. Structural improvement in operating efficiency or scale is required to convert healthy gross margins into sustainable operating profitability.
Negative Return On EquityA negative ROE signals capital is not generating shareholder returns, undermining long-term capital efficiency. Even with revenue and cash flow gains, the company must translate growth into positive returns through margin recovery or more productive use of equity capital.
Kuros Biosciences News
KURN FAQ
What was Kuros Biosciences Ltd.’s price range in the past 12 months?
Kuros Biosciences Ltd. lowest stock price was CHF14.00 and its highest was CHF34.20 in the past 12 months.
What is Kuros Biosciences Ltd.’s market cap?
Kuros Biosciences Ltd.’s market cap is CHF1.01B.
When is Kuros Biosciences Ltd.’s upcoming earnings report date?
Kuros Biosciences Ltd.’s upcoming earnings report date is Mar 10, 2026 which is in 33 days.
How were Kuros Biosciences Ltd.’s earnings last quarter?
Kuros Biosciences Ltd. released its earnings results on Aug 14, 2025. The company reported -CHF0.052 earnings per share for the quarter, missing the consensus estimate of N/A by -CHF0.052.
Is Kuros Biosciences Ltd. overvalued?
According to Wall Street analysts Kuros Biosciences Ltd.’s price is currently Undervalued.
Does Kuros Biosciences Ltd. pay dividends?
Kuros Biosciences Ltd. does not currently pay dividends.
What is Kuros Biosciences Ltd.’s EPS estimate?
Kuros Biosciences Ltd.’s EPS estimate is 0.
How many shares outstanding does Kuros Biosciences Ltd. have?
Kuros Biosciences Ltd. has 39,175,300 shares outstanding.
What happened to Kuros Biosciences Ltd.’s price movement after its last earnings report?
Kuros Biosciences Ltd. reported an EPS of -CHF0.052 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.311%.
Which hedge fund is a major shareholder of Kuros Biosciences Ltd.?
Currently, no hedge funds are holding shares in CH:KURN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Kuros Biosciences Ltd.
Kuros Biosciences AG, a biopharmaceutical company, engages in the commercialization and development of biopharmaceutical products for tissue repair and bone regeneration in the United States, the European Union, and internationally. It operates through Medical Devices, Pharmaceuticals, and Legacy Portfolio. The company's orthobiologics pipeline products include MagnetOs Granules and MagnetOs Putty in EU and US for the treatment of orthopedics, spinal, and dental problems. Its fibrin/PTH orthobiologics pipeline products comprise KUR-111, which has completed Phase 2b clinical trial for the treatment of tibial plateau fractures; and KUR-113, which completed Phase 2b clinical trial for the treatment of tibial shaft fractures, as well as is in the Phase II trial for the treatment of spinal interbody fusion. The company's sealants pipeline products include Neuroseal EU and US, synthetic tissue sealant for the prevention of cerebrospinal fluid leakage following cranial or spinal surgery. It has collaboration with Checkmate Pharmaceuticals LLC for the development of CYT003 for the treatment of oncology. The company is headquartered in Schlieren, Switzerland.
KURN Stock 12 Month Forecast
Average Price Target
CHF36.50
▲(29.62% Upside)
Technical Analysis
Molecular Partners AG
―
Basilea Pharmaceutica
―
Idorsia Ltd
―
Newron Pharmaceuticals SpA
―
Santhera Pharmaceuticals Holding
―
Options Prices
Currently, No data available
---